Novo buys majority stake in BBI Group at $562m-plus enterprise value

Novo Holdings’ investment in BBI is part of its Principal Investments strategy targeting investments in well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers.

Novo Holdings has acquired a majority stake in BBI Group for an enterprise value of over GBP 400 million ($562 million). The seller is Exponent Private Equity. BBI, a supplier to global diagnostics and life sciences industries, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. Lazard advised Novo on the deal.

PRESS RELEASE

Novo Holdings A/S, a leading global life sciences investor, today announced it has acquired BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, from Exponent for an enterprise value of over GBP 400 million.

Novo Holdings will be the majority shareholder of the company.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests.

BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents.

“We are proud to be the next owners of BBI. Diagnostics is a very attractive space which, with an enhanced global focus on preventative medicine, will play an increasingly important part in improving health outcomes for patients around the world.  We see tremendous opportunities for both organic and inorganic growth for the company. Novo Holdings is looking forward to contributing its considerable industry expertise and extensive network in supporting the talented team at BBI,” said Johan Hueffer, Senior Partner at Novo Holdings.

Mario Gualano, Group CEO of BBI, said: “We are delighted to be working with Novo Holdings, a team with a strong track record and a shared vision for growth and innovation. In the last five years, we have grown revenues and profitability considerably through investing in our products and services, people, and world-class infrastructure. We now have a fully invested and scalable platform to deliver future growth in a large and fast-growing market.”

Headquartered in Copenhagen, with a presence in San Francisco, Boston, London and Singapore, Novo Holdings is a world-leading life science investor with a focus on creating long-term value. The company has a portfolio of more than 120 life science companies and total assets of EUR 61 billion at the end of 2020. The company is fully owned by the Novo Nordisk Foundation, one of the world’s largest foundations. Through its investments, Novo Holdings aims to make a growing and positive impact on health, science and society by generating attractive long-term returns on the assets of the Foundation. Since 2010, the Foundation has donated more than DKK 30 billion (€4 billion) for projects improve the lives of people and the sustainability of society.

Novo Holdings’ investment in BBI is part of its Principal Investments strategy targeting investments in well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers.

In addition to capital and engagement, Novo Holdings provides access to an extensive network within the life science industry and uses its experience and expertise to actively support management in realizing its strategic ambitions.

Lazard served as financial advisor to Novo Holdings. Kromann Reumert, Latham & Watkins, and Linklaters served as legal advisors.

About BBI

BBI is a leading supplier of products and services to the global diagnostics and life sciences industries. The business has manufacturing sites spanning four continents and is headquartered in Crumlin, Wales. The Group’s brand, BBI Solutions, has served the global diagnostics industry for over 30 years, offering lateral flow development and manufacturing services with a core focus on antibody development, gold conjugation, lateral flow test manufacture and mobile diagnostic solutions with Novarum™ technology.

About Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.

About the Novo Nordisk Foundation

The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. It has two objectives: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group; and 2) to support scientific, humanitarian and social causes.

The vision of the Foundation is to contribute significantly to research and development that improves the lives of people and the sustainability of society. Since 2010, the Foundation has donated more than DKK 30 billion (€4 billion), primarily for research at public institutions and hospitals in Denmark and the other Nordic countries. Read more at www.novonordiskfonden.dk/en